Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
DetailsGuangzhou, China --(BUSINESSWIRE)--Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceuticalcompany, today announced that dosing has begun in a Phase III clinical studyfor BAT2306, a proposed biosimilar of Cosentyx® (secukinumab). The clinical study is a randomized,double-blind, para...
Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177) ,a commercial-stage biopharmaceutical company, today announced that dosing hasbegun in a Phase I clinical study to compare the pharmacokinetics and safety ofBAT2606, a proposed biosimilar of Nucala ® (mepolizumab), toUS-sourc...
Guangzhou,China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), acommercial-stage biopharmaceutical company, announced today the details of its poster presentation at the VaccinesSummit 2022, being held fromOctober 11-13inWashingtonD.C. Bio-Thera will present research andpreclinical resul...